BR112014029851A2 - composto, inibidores da atividade da enzima ros1 quinase e da enzima ntrk quinase, composição farmacêutica, agente antitumor, agente terapêutico para um tumor, método para tratamento de um tumor, e, agente para tratamento de um tumor - Google Patents

composto, inibidores da atividade da enzima ros1 quinase e da enzima ntrk quinase, composição farmacêutica, agente antitumor, agente terapêutico para um tumor, método para tratamento de um tumor, e, agente para tratamento de um tumor

Info

Publication number
BR112014029851A2
BR112014029851A2 BR112014029851A BR112014029851A BR112014029851A2 BR 112014029851 A2 BR112014029851 A2 BR 112014029851A2 BR 112014029851 A BR112014029851 A BR 112014029851A BR 112014029851 A BR112014029851 A BR 112014029851A BR 112014029851 A2 BR112014029851 A2 BR 112014029851A2
Authority
BR
Brazil
Prior art keywords
tumor
agent
treating
kinase enzyme
enzyme activity
Prior art date
Application number
BR112014029851A
Other languages
English (en)
Other versions
BR112014029851B1 (pt
Inventor
Yoshikawa Kenji
Kiga Masaki
Tanaka Ryoichi
Takeda Yasuyuki
Kagoshima Yoshiko
Hamada Yoshito
Tominaga Yuichi
Yamamoto Yuko
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Publication of BR112014029851A2 publication Critical patent/BR112014029851A2/pt
Publication of BR112014029851B1 publication Critical patent/BR112014029851B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems

Abstract

1 / 1 resumo “composto, inibidores da atividade da enzima ros1 quinase e da enzima ntrk quinase, composiã‡ãƒo farmacãšutica, agente antitumor, agente terapãšutico para um tumor, mã‰todo para tratamento de um tumor, e, agente para tratamento de um tumor” a presente invenã§ã£o prov㪠um composto ãºtil no tratamento de tumores por meio de aã§ã£o inibitã³ria da atividade da enzima ros1 quinase e de aã§ã£o inibitã³ria da enzima ntrk quinase, ou um sal farmaceuticamente aceitã¡vel do mesmo. um composto tendo uma estrutura imidazo[1,2- b]piridazina, representado pela fã³rmula geral (i), um sal farmaceuticamente aceitã¡vel do mesmo, ou composiã§ãµes farmacãªuticas que compreendem tais 4 compostos. (na fã³rmula, râ¹, g, t, yâ¹, yâ², yâ³, e y sã£o tais como definidos na presente descriã§ã£o).
BR112014029851-3A 2012-06-04 2013-06-03 Composto, inibidores da atividade da enzima ros1 quinase e da enzima ntrk quinase, composição farmacêutica, agente antitumor, agente terapêutico para um tumor, agente para tratamento de um tumor, e uso do referido composto BR112014029851B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2012127079 2012-06-04
JP2012-127079 2012-06-04
PCT/JP2013/065328 WO2013183578A1 (ja) 2012-06-04 2013-06-03 キナーゼ阻害剤としてのイミダゾ[１，２－ｂ]ピリダジン誘導体

Publications (2)

Publication Number Publication Date
BR112014029851A2 true BR112014029851A2 (pt) 2017-06-27
BR112014029851B1 BR112014029851B1 (pt) 2023-01-03

Family

ID=49711970

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014029851-3A BR112014029851B1 (pt) 2012-06-04 2013-06-03 Composto, inibidores da atividade da enzima ros1 quinase e da enzima ntrk quinase, composição farmacêutica, agente antitumor, agente terapêutico para um tumor, agente para tratamento de um tumor, e uso do referido composto

Country Status (32)

Country Link
US (2) US9187489B2 (pt)
EP (1) EP2857404B1 (pt)
JP (1) JP5814467B2 (pt)
KR (1) KR101781255B1 (pt)
CN (1) CN104520300B (pt)
AU (1) AU2013272701B2 (pt)
BR (1) BR112014029851B1 (pt)
CA (1) CA2874819C (pt)
CO (1) CO7160119A2 (pt)
CY (1) CY1119607T1 (pt)
DK (1) DK2857404T3 (pt)
ES (1) ES2648228T3 (pt)
HK (1) HK1207374A1 (pt)
HR (1) HRP20171724T1 (pt)
HU (1) HUE037221T2 (pt)
IL (1) IL236075A (pt)
IN (1) IN2014MN02497A (pt)
LT (1) LT2857404T (pt)
MX (1) MX357021B (pt)
MY (1) MY170326A (pt)
NO (1) NO2857404T3 (pt)
NZ (1) NZ702574A (pt)
PH (1) PH12014502721B1 (pt)
PL (1) PL2857404T3 (pt)
PT (1) PT2857404T (pt)
RS (1) RS56625B1 (pt)
RU (1) RU2635917C2 (pt)
SG (1) SG11201408052WA (pt)
SI (1) SI2857404T1 (pt)
TW (1) TWI585088B (pt)
WO (1) WO2013183578A1 (pt)
ZA (1) ZA201408843B (pt)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5503655B2 (ja) 2008-09-22 2014-05-28 アレイ バイオファーマ、インコーポレイテッド Ｔｒｋキナーゼ阻害剤としての置換イミダゾ［１，２ｂ］ピリダジン化合物
SI2350071T1 (sl) 2008-10-22 2014-05-30 Array Biopharma, Inc. Substituirane pirazolo(1,5-a)pirimidinske spojine kot Trk kinazni inhibitorji
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
ES2628418T3 (es) 2010-05-20 2017-08-02 Array Biopharma, Inc. Compuestos macrocíclicos como inhibidores de la TRK cinasa
CN104470918A (zh) 2012-05-30 2015-03-25 日本新药株式会社 芳香族杂环衍生物及医药
CN106132967B (zh) * 2014-03-27 2019-05-28 詹森药业有限公司 作为ros1抑制剂的化合物
KR102455519B1 (ko) * 2014-03-27 2022-10-14 얀센 파마슈티카 엔.브이. ＲＯＳ1 저해제로서의 치환된 4,5,6,7-테트라히드로피라졸로[1,5-ａ]피라진 유도체 및 5,6,7,8-테트라히드로-4Ｈ-피라졸로[1,5-ａ][1,4]디아제핀 유도체
CA2946416C (en) * 2014-04-25 2022-07-19 Exelixis, Inc. Method of treating lung adenocarcinoma
CN113354649A (zh) 2014-11-16 2021-09-07 阵列生物制药公司 一种新的晶型
TN2017000502A1 (en) 2015-06-01 2019-04-12 Loxo Oncology Inc Methods of diagnosing and treating cancer
CN107847765B (zh) 2015-06-18 2021-05-04 89生物有限公司 1,4-取代的哌啶衍生物
JP6986972B2 (ja) 2015-06-18 2021-12-22 エイティナイン バイオ リミテッド 置換４−ベンジル及び４−ベンゾイルピペリジン誘導体
SI3322706T1 (sl) 2015-07-16 2021-04-30 Array Biopharma, Inc. Substituirane pirazolo(1,5-A)piridinske spojine kot zaviralci ret-kinaze
US10724102B2 (en) 2015-10-26 2020-07-28 Loxo Oncology, Inc. Point mutations in TRK inhibitor-resistant cancer and methods relating to the same
CN106854174A (zh) * 2015-12-08 2017-06-16 湖南华腾制药有限公司 一种4位取代哌啶衍生物的制备方法
BR112018070017A2 (pt) 2016-04-04 2019-02-05 Loxo Oncology Inc métodos de tratamento de cânceres pediátricos
CU20180125A7 (es) 2016-04-04 2019-05-03 Loxo Oncology Inc Formulaciones líquidas de (s)-n-(5-((r)-2-(2,5-difluorofenil) -pirrolidin-1-il)-pirazolo[1,5-alpirimidin-3-il)-3 hidroxipirrolidina-1-carboxamida
US10045991B2 (en) 2016-04-04 2018-08-14 Loxo Oncology, Inc. Methods of treating pediatric cancers
AU2017268371B2 (en) 2016-05-18 2020-11-19 Array Biopharma Inc. Preparation of (S)-N-(5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo(1,5-A)pyrimidin-3-y l)-3-hydroxypyrrolidine-1-carboxamide
CN107400082A (zh) * 2016-05-19 2017-11-28 湖南华腾制药有限公司 一种取代哌啶衍生物的制备方法
TWI704148B (zh) 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
JOP20190077A1 (ar) 2016-10-10 2019-04-09 Array Biopharma Inc مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret
JOP20190072A1 (ar) 2016-10-13 2019-04-07 Glaxosmithkline Ip Dev Ltd مشتقات 1، 3 سيكلوبوتان ثنائي الاستبدال أو آزيتيدين كمثبطات للإنزيم المخلق للبروستاجلاندين d المكون للدم
JOP20190092A1 (ar) 2016-10-26 2019-04-25 Array Biopharma Inc عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
US11168090B2 (en) 2017-01-18 2021-11-09 Array Biopharma Inc. Substituted pyrazolo[1,5-a]pyrazines as RET kinase inhibitors
WO2018136663A1 (en) 2017-01-18 2018-07-26 Array Biopharma, Inc. Ret inhibitors
US11028091B2 (en) * 2017-03-14 2021-06-08 Daiichi Sankyo Company, Limited Method for producing 3, 6-disubstituted imidazo[1, 2-b]pyridazine derivative
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
US10180422B1 (en) 2017-08-22 2019-01-15 Scripps Health Methods of treating a neuroendocrine tumor
TWI791053B (zh) 2017-10-10 2023-02-01 美商亞雷生物製藥股份有限公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物
TWI812649B (zh) 2017-10-10 2023-08-21 美商絡速藥業公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物
CA3080157A1 (en) 2017-10-26 2019-05-02 Array Biopharma Inc. Formulations of a macrocyclic trk kinase inhibitor
CN109748902B (zh) * 2017-11-02 2020-11-06 杭州科巢生物科技有限公司 一种盐酸安罗替尼的制备方法
US20230242670A1 (en) * 2017-11-29 2023-08-03 Seoul National University R&Db Foundation Anti-ros1 antibody and use thereof
CN108129288B (zh) * 2017-12-27 2021-01-22 上海毕得医药科技股份有限公司 一种反式-3-羟基环丁基甲酸的合成方法
CA3087578C (en) 2018-01-18 2023-08-08 Array Biopharma Inc. Substituted pyrazolo[3,4-d]pyrimidine compounds as ret kinase inhibitors
CN111971286B (zh) 2018-01-18 2023-04-14 阿雷生物药品公司 作为RET激酶抑制剂的取代的吡咯并[2,3-d]嘧啶化合物
WO2019143994A1 (en) 2018-01-18 2019-07-25 Array Biopharma Inc. Substituted pyrazolyl[4,3-c]pyridinecompounds as ret kinase inhibitors
CA3095366A1 (en) 2018-03-29 2019-10-03 Loxo Oncology, Inc. Treatment of trk-associated cancers
CA3224945A1 (en) 2018-07-31 2020-02-06 Loxo Oncology, Inc. Spray-dried dispersions, formulations, and polymorphs of (s)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropan-2-yl)-1h-pyrazole-4-carboxamide
JP2022500383A (ja) 2018-09-10 2022-01-04 アレイ バイオファーマ インコーポレイテッド Ｒｅｔキナーゼ阻害剤としての縮合複素環式化合物
WO2020131674A1 (en) 2018-12-19 2020-06-25 Array Biopharma Inc. 7-((3,5-dimethoxyphenyl)amino)quinoxaline derivatives as fgfr inhibitors for treating cancer
EP3898626A1 (en) 2018-12-19 2021-10-27 Array Biopharma, Inc. Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of fgfr tyrosine kinases
EP3936192A4 (en) * 2019-03-06 2022-11-16 Daiichi Sankyo Company, Limited PYRROLOPYRAZOL DERIVATIVES
KR20210142154A (ko) 2019-03-21 2021-11-24 옹쎄오 암 치료를 위한 키나제 억제제와 조합된 dbait 분자
JP7420403B2 (ja) * 2019-05-08 2024-01-23 ティーワイケー メディシンズ インコーポレーテッド キナーゼ阻害剤として使用される化合物およびその応用
CA3159348A1 (en) 2019-11-08 2021-05-14 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
AR122159A1 (es) * 2020-05-28 2022-08-17 Novartis Ag Inhibidores de mll1 y agentes antineoplásicos
CN114957259A (zh) * 2021-02-25 2022-08-30 南京明德新药研发有限公司 氰基取代的芳香双环类化合物及其应用
CA3223035A1 (en) * 2021-07-01 2023-01-05 Anheart Therapeutics (Hangzhou) Co., Ltd. Crystalline forms of 3-{4-[(2r)-2-aminopropoxy]phenyl}-n-[(1r)- 1-(3-fluorophenyl) ethyl]imidazo[1,2-b]pyridazin-6-amine and salts thereof
WO2023220967A1 (en) * 2022-05-18 2023-11-23 Anheart Therapeutics (Hangzhou) Co., Ltd. Method for producing 3,6-disubstituted-imidazo[1,2-b]pyridazine compounds
CN114989176A (zh) * 2022-07-08 2022-09-02 深圳市新樾生物科技有限公司 咪唑并哒嗪类衍生物及其应用
CN115197115A (zh) * 2022-08-25 2022-10-18 成都金博汇康医药科技有限公司 一种手性5-氧代吡咯烷-3-甲酸的制备方法与应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6399780B1 (en) 1999-08-20 2002-06-04 Cephalon, Inc. Isomeric fused pyrrolocarbazoles and isoindolones
JP2004508366A (ja) 2000-09-01 2004-03-18 グラクソ　グループ　リミテッド オキシインドール誘導体
WO2002020479A1 (en) 2000-09-01 2002-03-14 Glaxo Group Limited Substituted oxindole derivatives as tyrosine kinase inhibitors
JP2003231687A (ja) 2002-02-04 2003-08-19 Japan Tobacco Inc ピラゾリル縮合環化合物及びその医薬用途
MY141220A (en) 2003-11-17 2010-03-31 Astrazeneca Ab Pyrazole derivatives as inhibitors of receptor tyrosine kinases
EP1742921A2 (en) 2004-04-21 2007-01-17 AstraZeneca AB Pyrazole derivatives useful for the treatment of cancer
WO2006070943A1 (ja) 2004-12-28 2006-07-06 Takeda Pharmaceutical Company Limited 縮合イミダゾール化合物およびその用途
MX2007009437A (es) 2005-02-04 2007-08-16 Astrazeneca Ab Derivados de pirazolilaminopiridina utiles como inhibidores de cinasa.
RU2405780C2 (ru) 2005-02-16 2010-12-10 Астразенека Аб Химические соединения
US7622482B2 (en) 2005-02-16 2009-11-24 Astrazeneca Chemical compounds
EP1910369A1 (en) 2005-07-29 2008-04-16 Astellas Pharma Inc. Fused heterocycles as lck inhibitors
EP1912987A1 (en) * 2005-08-01 2008-04-23 F. Hoffmann-Roche AG Heterocyclic benzylamino derivatives, their manufacture and use as pharmaceutical agents
DE102005042742A1 (de) 2005-09-02 2007-03-08 Schering Ag Substituierte Imidazo[1,2b]pyridazine als Kinase-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
DE102006029447A1 (de) * 2006-06-21 2007-12-27 Bayer Schering Pharma Ag Oxo-substituierte Imidazo[1,2b]pyridazine, deren Herstellung und Verwendung als Arzneimittel
WO2008052734A1 (en) 2006-10-30 2008-05-08 Novartis Ag Heterocyclic compounds as antiinflammatory agents
RU2487875C2 (ru) * 2006-11-06 2013-07-20 Толеро Фармасьютикалз,Инк. ПРОИЗВОДНЫЕ ИМИДАЗО [1,2-b]ПИРИДАЗИНА И ПИРАЗОЛО[1,5-a]ПИРИМИДИНА И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ИНГИБИТОРА ПРОТЕИНКИНАЗ
WO2008072682A1 (ja) * 2006-12-15 2008-06-19 Daiichi Sankyo Company, Limited イミダゾ［１，２－ｂ］ピリダジン誘導体
JP2009227599A (ja) * 2008-03-21 2009-10-08 Daiichi Sankyo Co Ltd イミダゾピリダジン誘導体
MX2010012457A (es) 2008-05-13 2010-12-07 Irm Llc Heterociclos que contienen nitrogeno fusionado y composiciones de los mismos como inhibidores de cinasa.
JP5503655B2 (ja) 2008-09-22 2014-05-28 アレイ バイオファーマ、インコーポレイテッド Ｔｒｋキナーゼ阻害剤としての置換イミダゾ［１，２ｂ］ピリダジン化合物
KR101147550B1 (ko) * 2009-10-22 2012-05-17 한국과학기술연구원 단백질 키나아제 저해활성을 가지는 2,7-치환된 티에노［3,2-ｄ］피리미딘 화합물
WO2012005299A1 (ja) 2010-07-07 2012-01-12 日本新薬株式会社 Ｒｏｓチロシンキナーゼ阻害剤
WO2012125667A1 (en) 2011-03-17 2012-09-20 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF

Also Published As

Publication number Publication date
IL236075A0 (en) 2015-02-01
CO7160119A2 (es) 2015-01-15
JP5814467B2 (ja) 2015-11-17
MY170326A (en) 2019-07-17
CN104520300A (zh) 2015-04-15
TWI585088B (zh) 2017-06-01
US9187489B2 (en) 2015-11-17
KR101781255B1 (ko) 2017-09-22
JPWO2013183578A1 (ja) 2016-01-28
CA2874819C (en) 2017-06-20
PT2857404T (pt) 2017-11-23
KR20150014942A (ko) 2015-02-09
EP2857404A4 (en) 2016-01-20
HK1207374A1 (en) 2016-01-29
US20160046639A1 (en) 2016-02-18
LT2857404T (lt) 2017-11-10
NO2857404T3 (pt) 2018-01-20
PH12014502721A1 (en) 2015-02-02
CY1119607T1 (el) 2018-04-04
RU2014153627A (ru) 2016-08-10
BR112014029851B1 (pt) 2023-01-03
AU2013272701A1 (en) 2015-01-15
HUE037221T2 (hu) 2018-08-28
EP2857404A1 (en) 2015-04-08
MX357021B (es) 2018-06-25
CA2874819A1 (en) 2013-12-12
SI2857404T1 (sl) 2017-11-30
PL2857404T3 (pl) 2018-04-30
US20150051190A1 (en) 2015-02-19
DK2857404T3 (en) 2017-12-04
RU2635917C2 (ru) 2017-11-17
MX2014014803A (es) 2015-02-12
EP2857404B1 (en) 2017-08-23
IL236075A (en) 2017-10-31
RS56625B1 (sr) 2018-03-30
ES2648228T3 (es) 2017-12-29
IN2014MN02497A (pt) 2015-07-17
SG11201408052WA (en) 2015-01-29
TW201400486A (zh) 2014-01-01
ZA201408843B (en) 2016-01-27
HRP20171724T1 (hr) 2018-01-12
NZ702574A (en) 2016-07-29
AU2013272701A2 (en) 2015-01-22
AU2013272701B2 (en) 2017-12-21
PH12014502721B1 (en) 2015-02-02
WO2013183578A1 (ja) 2013-12-12
CN104520300B (zh) 2016-12-21
US9751887B2 (en) 2017-09-05

Similar Documents

Publication Publication Date Title
BR112014029851A2 (pt) composto, inibidores da atividade da enzima ros1 quinase e da enzima ntrk quinase, composição farmacêutica, agente antitumor, agente terapêutico para um tumor, método para tratamento de um tumor, e, agente para tratamento de um tumor
BR112018004175B8 (pt) Composto pirazolo[3,4-d]pirimidina, composição farmacêutica e usos terapêuticos do dito composto
BR112015028501B8 (pt) Compostos derivados de bipirazol, seus sais, composição compreendendo o composto ou o sal, método de inibição in vitro de uma atividade de jak1, e processo de preparação de sal de ácido fosfórico
AR063628A1 (es) Compuestos de piridinona utiles para el tratamiento de cancer
BR112015014585A2 (pt) composto, composição farmacêutica, e, método de tratamento de um ser humano
BR112015026023A2 (pt) derivados de 2- aminopirido[4,3-d]pirimidin-5-ona e seu uso como inibidores de wee-1
BR112015014592A2 (pt) composto, composição farmacêutica, e, método para o tratamento de um humano
BR112019006047A2 (pt) compostos, um ou dois ou mais compostos, sal farmaceuticamente aceitável, sal metanossulfonato, inibidor de quinase ret, medicamento, usos do composto e de um composto, métodos para tratar ou prevenir câncer e para tratar ou prevenir câncer em um indivíduo, e, composição farmacêutica
BR112015013611A2 (pt) composto, e, composição farmacêutica
BR112015009168A2 (pt) composto de fórmula estrutural xi, uso de um composto, composição farmacêutica, método de tratamento de uma doença mediada pela pde4 em um sujeito, método de modulação de uma função mediada pela pde4 em um sujeito, método de alcançar um efeito em um paciente e método para inibir a pde4
DOP2010000013A (es) Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas
BR112015012295A2 (pt) métodos para tratar um paciente, e, kit para identificar um paciente com câncer
EA201692506A3 (ru) Ингибиторы репликации вирусов гриппа
BR112015015653A8 (pt) composto, método de preparação dos compostos, composto para uso, composição farmacêutica e métodos in vitro
MX2013012981A (es) Compuestos de indazol sustituidos como inhibidores de las cinasas de proteina.
BR112015021999A8 (pt) inibidores de indoleamina 2,3-dioxigenase (ido), seus usos, composição farmacêutica, e método para inibir a atiavidade de indoleamina 2,3-dioxigenase
BR112015022462A8 (pt) inibidores de ido, composição farmacêutica, método de inibição de atividade de indolamina 2,3-dioxigenase e uso dos referidos inibidores
UY30559A1 (es) Derivados de morfolino pirimidina, procesos de preparacion, composiciones conteniéndolos y aplicaciones
DOP2010000011A (es) Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas
BR112015015635A8 (pt) composto, método de preparação dos compostos, composição farmacêutica e método in vitro de previsão
DOP2013000192A (es) Compuestos y composiciones como inhibidores de la trk
BR112014019052A8 (pt) Inibidores seletivos de cdk8/cdk19 e seu uso em métodos antimetastáticos e quimiopreventivos para câncer
CO6251364A2 (es) Derivados de morfolino pirimidina utilazdos en enfermedades relacionados con mtor quinasa y/o p13k
BR112015015477A2 (pt) derivados de 2,3-di-hidro-isoindol-1-ona e métodos de uso dos mesmos como inibidores de btk
BR112013032720A2 (pt) "derivados de azetidinil fenil, piridil ou pirazinil carboxamida como inibidores de jak, composição e uso dos referidos derivados"

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA.

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 03/06/2013, OBSERVADAS AS CONDICOES LEGAIS